EA200100108A1 - Применение биогенных сульфаматов эстрогенов для гормонзаместительной терапии - Google Patents

Применение биогенных сульфаматов эстрогенов для гормонзаместительной терапии

Info

Publication number
EA200100108A1
EA200100108A1 EA200100108A EA200100108A EA200100108A1 EA 200100108 A1 EA200100108 A1 EA 200100108A1 EA 200100108 A EA200100108 A EA 200100108A EA 200100108 A EA200100108 A EA 200100108A EA 200100108 A1 EA200100108 A1 EA 200100108A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sulfamate
estrone
application
hormone
sulfamats
Prior art date
Application number
EA200100108A
Other languages
English (en)
Other versions
EA003371B1 (ru
Inventor
Вальтер Эльгер
Пекка Лянтеенмяки
Матти Лехтинен
Гудрун Реддерзен
Хольгер Циммерманн
Михаэль Ёттель
Зигфрид Шварц
Original Assignee
Йенафарм Гмбх Энд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Йенафарм Гмбх Энд Ко. Кг filed Critical Йенафарм Гмбх Энд Ко. Кг
Publication of EA200100108A1 publication Critical patent/EA200100108A1/ru
Publication of EA003371B1 publication Critical patent/EA003371B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Abstract

В заявке описано применение биогенных сульфаматов эстрогена для периодического введения оральным путем при гормонзаместительной терапии (ГЗТ). Периодическое введение осуществляют с интервалами в 2-40 дней. Согласно изобретению предлагается также дополнительное введение гестагенов, предпочтительно непрерывное введение, осуществляемое с использованием имплантата или с использованием внутриматочной системы высвобождения (ВМСВ). В качестве биогенного сульфамата эстрогена могут применяться сульфамат эстрона, сульфамат эстрадиола, сульфамат эстриола или N-ацилсульфамат эстрона, эстрадиола или эстриола, имеющий до 7 атомов углерода в ацильной цепи, или комбинация, включающая два или большее количество из указанных действующих веществ.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100108A 1998-07-28 1999-05-13 Применение биогенных сульфаматов эстрогенов для гормонзаместительной терапии EA003371B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19834931A DE19834931A1 (de) 1998-07-28 1998-07-28 Verwendung von biogenen Estrogenen zur Hormonsubstitutionstherapie
PCT/DE1999/001496 WO2000006175A1 (de) 1998-07-28 1999-05-13 Verwendung von biogenen estrogenssulfamaten zur hormonsubstitutionstherapie

Publications (2)

Publication Number Publication Date
EA200100108A1 true EA200100108A1 (ru) 2001-12-24
EA003371B1 EA003371B1 (ru) 2003-04-24

Family

ID=7876248

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100108A EA003371B1 (ru) 1998-07-28 1999-05-13 Применение биогенных сульфаматов эстрогенов для гормонзаместительной терапии

Country Status (28)

Country Link
US (1) US7053077B1 (ru)
EP (1) EP1100509B1 (ru)
JP (1) JP4891479B2 (ru)
KR (1) KR20010072082A (ru)
CN (1) CN1311683A (ru)
AP (1) AP2001002054A0 (ru)
AR (1) AR016502A1 (ru)
AT (1) ATE292468T1 (ru)
AU (1) AU766019B2 (ru)
BG (1) BG105171A (ru)
BR (1) BR9912466A (ru)
CA (1) CA2338558A1 (ru)
CO (1) CO5261567A1 (ru)
DE (2) DE19834931A1 (ru)
EA (1) EA003371B1 (ru)
EE (1) EE200100053A (ru)
HK (1) HK1040192A1 (ru)
HU (1) HUP0102913A3 (ru)
IL (1) IL141081A0 (ru)
IS (1) IS5819A (ru)
MX (1) MXPA01000548A (ru)
NO (1) NO20010468L (ru)
NZ (1) NZ509521A (ru)
PL (1) PL345588A1 (ru)
SK (1) SK1292001A3 (ru)
TR (1) TR200100234T2 (ru)
WO (1) WO2000006175A1 (ru)
ZA (1) ZA200100743B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006027A1 (en) 2001-07-13 2003-01-23 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
US8026229B2 (en) 2001-08-13 2011-09-27 Sterix Limited Antitumor-active 2-alkoxyestradiol sulfamates
US8282612B1 (en) 2008-03-07 2012-10-09 Denise H. Miller Methods and devices for intrauterine absorption
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2647379A1 (en) * 2012-04-05 2013-10-09 PregLem S.A. Combined use of a steroid sulfatase inhibitor for the treatment of endometriosis
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9078786B1 (en) 2012-10-19 2015-07-14 Denise H. Miller Methods and devices for collecting body fluids
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314694A (en) * 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
AU7075594A (en) * 1993-06-29 1995-01-24 Leiras Oy Pack for use in, and method of hormonal replacement therapy
DE4429397C2 (de) * 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE4447715C2 (de) * 1994-08-09 1998-02-05 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Behandlung von Prostatakarzinomen
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
DE19610635A1 (de) * 1996-03-11 1997-09-18 Schering Ag Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie
IL123422A (en) * 1997-03-05 2003-05-29 Akzo Nobel Nv USE OF 7alpha-METHYL-17alpha-ETHYNYL-ESTRANE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS OR THE TREATMENT OF ATHEROSCLEROSIS
JP2002520346A (ja) * 1998-07-17 2002-07-09 ファルマシア・アンド・アップジョン・カンパニー 避妊用皮下メドロキシプロゲステロンアセタート

Also Published As

Publication number Publication date
EA003371B1 (ru) 2003-04-24
EP1100509B1 (de) 2005-04-06
EE200100053A (et) 2002-06-17
HUP0102913A3 (en) 2002-03-28
BG105171A (bg) 2001-07-31
DE19834931A1 (de) 2000-02-24
AU5148199A (en) 2000-02-21
TR200100234T2 (tr) 2001-06-21
CA2338558A1 (en) 2000-02-10
ZA200100743B (en) 2002-05-08
NO20010468L (no) 2001-03-27
IS5819A (is) 2001-01-19
CN1311683A (zh) 2001-09-05
NZ509521A (en) 2003-11-28
NO20010468D0 (no) 2001-01-26
KR20010072082A (ko) 2001-07-31
IL141081A0 (en) 2002-02-10
SK1292001A3 (en) 2001-07-10
PL345588A1 (en) 2001-12-17
BR9912466A (pt) 2001-04-17
CO5261567A1 (es) 2003-03-31
JP4891479B2 (ja) 2012-03-07
AP2001002054A0 (en) 2001-03-31
AU766019B2 (en) 2003-10-09
DE59911879D1 (de) 2005-05-12
US7053077B1 (en) 2006-05-30
JP2002521452A (ja) 2002-07-16
MXPA01000548A (es) 2002-04-08
EP1100509A1 (de) 2001-05-23
HK1040192A1 (zh) 2002-05-31
ATE292468T1 (de) 2005-04-15
AR016502A1 (es) 2001-07-04
HUP0102913A2 (hu) 2002-01-28
WO2000006175A1 (de) 2000-02-10

Similar Documents

Publication Publication Date Title
EA200100108A1 (ru) Применение биогенных сульфаматов эстрогенов для гормонзаместительной терапии
DK1272504T3 (da) 8.Beta-hydrocarbylsubstituerede östradiener til anvendelse som selektive östrogener
AR011480A1 (es) ACIL-ANILIDAS SUSTITUIDAS CON RADICALES (HETERO) CICLICOS, NO ESTEROIDALES, CON ACTIVIDAD GESTÁGENA Y ANDRoGENA MIXTA.
BR9709934A (pt) Kit de terapia de reposição hormonal e/ou contraceptivo uso de unidades de dosagem diária consistindo essecialmente de um progestogênio e processo de preparação de um sistema de liberação de droga
PT868188E (pt) Kit para a contracepcao em mamiferos femininos consistindo numa combinacao de gestagenio e estrogenio
HUP9800863A2 (hu) Gyógyszerszállító rendszer két vagy több hatóanyaghoz
ATE248853T1 (de) Pharmazeutische zusammensetzungen mit estra-1,3, 5(10)-trien-derivaten
BG101553A (en) Progesterone antagonist and antiestrogenous active compounds of general application for female contraceptives
NZ503890A (en) Oral contraceptives comprising non-uterotrophic anti-estrogens and progestin
ATE28752T1 (de) 1-alkyl-androsta-1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate.
EA200401544A1 (ru) 9α-ЗАМЕЩЁННЫЕ ЭСТРАТРИЕНЫ В КАЧЕСТВЕ ЭСТРОГЕНОВ ИЗБИРАТЕЛЬНОГО ДЕЙСТВИЯ
PE20010579A1 (es) Mesoprogestinas (modulares de receptores de progesterona) como componentes de anticonceptivos femeninos
YU77302A (sh) 8beta-hidrokarbil-supstituisani estratrieni kao selektivno delotvorni estrogeni
FI920843A0 (fi) 14a, 17a -tvaerbundna estratriener.
TH55261B (th) การใช้ไบโอเจนิคอีสโตรเจนซัลฟาเมทในการรักษาการทดแทนฮอร์โมน
DE59900775D1 (de) Ungesättigte 14,15-cyclopropano-androstane, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische präparate
TH55261A3 (th) การใช้ไบโอเจนิคอีสโตรเจนซัลฟาเมทในการรักษาการทดแทนฮอร์โมน
BR0010070A (pt) Uso de org 33245, kit contraceptivo, meio combinado para a dosagem de um progestogênio e um antiprogestogênio, e, métodos de contracepção, e de tratamento de sangramento uterino irregular ou de ruptura em uma fêmea utilizando uma preparação somente de progestogênio
RU2006126632A (ru) Стероиды, имеющие смешанный андрогенный и прогрестагенный профиль

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU